Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on
Background Topical Therapy. A Phase 3b Randomized, Double-Blind, Double-Dummy, Active-Controlled Multi-Center Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis.